Optimizing Treatment Outcomes in Advanced NSCLC with Concurrent Biomarker Testing - Episode 9

Key Takeaways for Concurrent Biomarker Testing in NSCLC

,

Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, emphasize the critical role of both tissue and liquid biopsies, the necessity of rapid time-to-treatment initiation, and the increasing likelihood of liquid biopsies becoming the standard of care for metastatic non-small cell lung cancer patients in the near future.

EP. 1: Optimizing NSCLC Patient Outcomes Through Concurrent Biomarker Testing
EP. 2: Concurrent NSCLC Biomarker Testing at Diagnosis
EP. 3: NCCN Guidelines: Optimizing NSCLC Treatment with Concurrent Biomarker Testing
EP. 4: Improving Time-to-Treatment for Patients With Non-Small Cell Lung Cancer
EP. 5: Biomarker Testing in Early-Stage NSCLC
EP. 6: Reflex Testing for Patients with Suspected Lung Cancer
EP. 7: Challenges of NSCLC Biomarker Testing in Clinical Practice
EP. 8: Overcoming Barriers to NSCLC Biomarker Testing
Now Viewing
EP. 9: Key Takeaways for Concurrent Biomarker Testing in NSCLC

Related Content:

Optimizing Treatment Outcomes in Advanced NSCLC with Concurrent Biomarker TestingThe US Oncology NetworkLung CancerOncLive News Network®
Perioperative Durvalumab Plus Chemotherapy Represents the Future of Personalized NSCLC Care
FDA Receives New BLA for Dato-DXd in Pretreated EGFR+ Advanced NSCLC
E-602 Plus Cemiplimab Elicits Preliminary Antitumor Activity, Is Safe in PD-(L)1–Resistant Solid Tumors